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ABSTRACT: We report herein the design and synthesis of a series of novel Sinefungin (SIN) 
derivatives, based on the structures of SIN and its analogue EPZ004777. Our results reveal that 
target compounds 1ad-af, 1ba-bb and 1bf-bh show better activity (IC50 = 4.56-20.16 µM) than 
EPZ004777 (IC50 = 35.19 µM). Surprisingly, SIN was founded to be not as active (IC50 > 50 µM) 
as we and other research groups predicted. Interestingly, the intermediates 9a-b and 11b display 
potent anti-ZIKV potency (IC50 = 6.33-29.98 µM), and compound 9a also exhibits acceptable 
cytotoxicity (CC50 > 200 µM), suggesting their promising potential to be leads for further 
development.  
 
1. Introduction 
   Zika virus (ZIKV) was first identified in 1947 in the Zika forest of Uganda, where it was 
isolated from the blood of sentinel rhesus macaques. [1] It belongs to the flavivirus genus of the 
Flaviviridae family, is related to yellow fever virus (YFV), dengue virus (DENV) and west nile 
virus (WNV). In the decades following its discovery, ZIKV posed little concern to the general 
public as it remained relatively dormant. The first outbreak occurred on the island of Yap in the 
federated states of Microesia in April 2007. [2-3] Subsequently, ZIKV strains have become more 
prevalent, leading to an increase in global epidemics. More than 60 countries and territories had 
reported ZIKV infection since the first epidemic. [4] Importantly, the ZIKV can lead to the rare 
birth defect microcephaly and other neurological disorders in infants and adults. [5] It was 
reported that over 3500 babies were born with microcephaly between Oct. 2015 and Jan. 2016 in 
Brazil. The world health organization (WHO) declared in November 2016 that the ZIKV is a 
highly significant and a long-term problem. [6]   
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Figure 1. Design of new SIN derivatives 
   To date, there are no clinically approved vaccines or antiviral drugs for the treatment of ZIKV 
infection. Sinefungin (SIN, Figure 1) was isolated from the fermentation broth of Streptomyces 
griseoleus NRRL 3739 by Eli Lilly as a potential antifungal antibiotic. [7-8] It is structurally 
similar to S-Adenosyl methionine (SAM) and acts as a competitive inhibitor of numerous 
Methyltransferases (Mtases). It was reported that SIN exhibited antitumor, [9] antiviral [10-11] 
and antiparasitic activity [12]. Recently, SIN was demonstrated to show considerable 
anti-flavivirus activity (WNV, DENV-2 and YFV). Since ZIKV belongs to the flavivirus family, 
we agreed with others [13-15] in speculating that SIN might also be a potential ZIKV inhibitor. 
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Scheme 1. Synthesis of the target compounds  
  SIN is water soluble, and displays a lower log P value of -3.01 (calculated by chemdraw 16.0) 
which limits its membrane permeability. [13, 16] EPZ004777, a SIN structural analogue 
containing a lipophilicity side chain, was developed as a potent histone methyltransferase 
inhibitor. [17] We hypothesized that EPZ004777 could address the issue of SIN membrane 
permeability while retaining the anti-ZIKV activity.  
  Recently, the crystal structural of ZIKV Mtase with SIN was resolved by Kamil Hercik et al. 
Based on the structural data, they suggested modification of the adenine moiety of SIN to 
increase selectivity and binding affinity of ZIKV Mtase. [14] Additionally, researchers from 
Novartis Institute for Tropical Disease (NITD) discovered NITD 10, a 
S-adenosyl-l-homocysteine (SAH) analogue with 3-chloro-benzyl at the N-6 position of adenine. 
It selectively inhibited DENV-3 Mtase (Ki = 0.002-0.24 µM) and WNV Mtase (Ki = 0.044-5.68 
µM) without suppressing host MTases (Ki > 50 µM). [18] Thus, we sought to design, synthesis 
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and evaluate a new series of SIN derivatives containing 3-fluoro- or chloro-benzyl moieties at 
N-6 position of adenine and a lipophilicity side chain (aryl W) while integrating the structure 
features of NITD 10 and EPZ004777.  
2. Results and discussion 
2.1. Chemistry 
The synthesis of new SIN derivatives 1 is shown in scheme 1. Coupling of the chloropurine 
2 with substituted benzyl amines in EtOH at reflux resulted in adenines 3a-b. The primary 
alcohol of 3a-b was converted to the corresponding amines 4a-b via standard Mitsunobu 
displacement with phthalimide followed by hydrazinolysis in 75-77% yields over two steps. 
Reductive amination of 4a-b with acetone in the presence of NaCNBH3 and acetic acid provided 
isopropyl amines 5a-b in good yields. Michael addition of compounds 5a-b with methyl acrylate 
in MeOH at reflux over 24 hours furnished 6a-b in a low yield, but under microwave radiation at 
90 oC over 3 hours gave 6a-b in 76-80% yields. Reduction of methyl esters 6a-b with LiAlH4 in 
THF afforded alcohols 7a-b, which upon Mitsunobu reaction and hydrazinolysis generated 
amines 8a-b. Treatment of 8a-b with isocyanate in DCM followed by removal of the acetonide 
protecting group with TFA furnished the SIN derivatives 1ab-af, and 1ba-bf. 
 
Scheme 2. Synthesis of compounds 9-12 
To achieve structurally diverse targets, the acetonide protecting group of the intermediates 
5-8 was also removed by TFA in DCM, as outlined in scheme 2. The resulting compounds 9-12 
were also tested for their anti-ZIKV activity.   
2.2. Anti-ZIKV activity 
All new SIN derivatives 1aa-ah, 1ba-bh, and deprotected intermediates 9-12 were evaluated 
for their in vitro anti-ZIKV activity in an infection-based cell culture model that utilizes a ZIKV 
strain SMGC and BHK cell line by Cell Titer-Glo Luminescent Cell Viability Assay (Promega). 
The ZIKV was obtained from the Institute of Microbiology, Chinese Academy of Sciences, 
Beijing, China. The IC50 values of the SIN derivatives 1aa-ah, 1ba-bh and intermediates 9-12 
along with SIN and EPZ004777 for comparison were summarized in µM in Tables 1 and 2, 
respectively. 
Surprisingly, SIN (IC50 > 50 µM) is not as active against the ZIKV as we predicted, whereas 
EPZ004777 displays considerable anti-ZIKV activity (IC50 = 35.19 µM). Among the target 
compounds, 1ad-af, 1ba-bb, and 1bf-bh exhibit potent activity (IC50 < 30 µM); 1aa-ac, 1ag-ah, 
and 1bc are not active against ZIKV; 1bd-be are failure to acquire anti-ZIKV activity in this 
model, possibly due to their high toxicity (CC50 = 6.35-6.73 µM) in BHK cell line. In particular, 
compounds 1ad-af, 1bb, and 1bf (IC50 = 4.56-6.99 µM) were found to be 5.0-7.7-fold more 
potent than the reference EPZ004777. 
Generally, compounds with chlorine as the aryl X substituent display higher activity than the 
corresponding fluorine analogues (1aa-ab vs 1ba-bb; 1af-ah vs 1bf-bh). Notably, this SAR 
result is consistent with an earlier report on the DENV-related SAR observations by NITD, [18] 
suggesting that the Mtase structures of ZIKV and DENV might be similar. When the aryl X 
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substituent is fluorine, compounds 1ad-af with 4-t-Bu-phenyl, 4-CF3-phenyl and 3-CF3-phenyl as 
the aryl W group show excellent anti-ZIKV potency (IC50 = 6.46-6.99 µM). In contrast, 
introduction of other aryl W substituents leads to a compete loss of activity (1aa-ac and 1ag-ah, 
IC50 > 50 µM). When the aryl X substituent is chlorine, apart from a few exceptions (1bc-be), all 
of these compounds display potent activity (IC50 < 30 µM), and the contribution of aryl W group 
to the activity is in this order: 3-CF3-phenyl > 4-Me-phenyl > cyclohexyl > 4-F-phenyl > t-Bu > 
4-methoxyphenyl.   
Subsequently, intermediates 9-12 were tested for their anti-ZIKV activity (Table 2). Most of 
the intermediates 10a-b, 11a and 12a-b are not active (IC50 > 50 µM) but 9a, 9b and 11b (IC50 = 
6.33-29.98 µM) fortunately display potent anti-ZIKV activity. Among them, compound 9b (IC50 
= 6.33 µM) demonstrated to be more potent than its fluorne analogue 10a. Interestingly, this SAR 
is similar as above in the SIN derivatives.   
Table 1. Structures and anti-ZIKV activity of the target compounds 
 
Compds. X W IC50 (µM)  CC50 (µM)  SI 
1aa F 4-F-phenyl >50 ND NA 
1ab F 4-Me-phenyl >50 ND NA 
1ac F 4-MeO-phenyl >50 ND NA 
1ad F 4-t-Bu-phenyl 6.65 ± 0.07 18.71±0.76 2.81 
1ae F 4-CF3-phenyl 6.46±0.22 20.27±0.93 3.14 
1af F 3-CF3-phenyl 6.99 ± 0.39 12.88±0.28 1.84 
1ag F t-Bu >50 ND NA 
1ah F Cyclohexyl >50 ND NA 
1ba Cl 4-F-phenyl 15.29 ± 8.37 20.01±7.83 1.31 
1bb Cl 4-Me-phenyl 5.80 ± 1.42 19.11±0.76 3.29 
1bc Cl 4-MeO-phenyl >50 ND NA 
1bd Cl 4-t-Bu-phenyl NA 6.73±0.02 NA 
1be Cl 4-CF3-phenyl NA 6.35±1.13 NA 
1bf Cl 3-CF3-phenyl 4.56 ± 3.84 5.88±1.62 1.29 
1bg Cl t-Bu 20.61 ± 0.38 58.49±1.16 2.84 
1bh Cl Cyclohexyl 12.24 ± 4.02 57.57±1.42 4.70 
SIN   >50 ND NA 
EPZ004777   35.19±7.02 >200 >5.68 
       ND, not detected; NA, not available.  
2.3. Cytotoxicity 
   The SIN derivatives and additional intermediates that displayed considerable anti-ZIKV 
activity (IC50 < 50 µM) were further evaluated for cytotoxicity test against BHK cell line by Cell 
Titer-Glo Luminescent Cell Viability Assay (Promega). Unfortunately, all the tested SIN 
derivatives (CC50 = 5.88-58.49 µM) exhibit higher cytotoxicity than EPZ004777 (CC50 > 200 
µM), and their selective indexes (SI = 1.29-4.70) are lower than EPZ004777 (SI > 5.68). The best 
compound 1bf displays the highest cytotoxicity (CC50 = 5.88 µM), the least 1bg also exhibits the 
lowest cytotoxicity (CC50 = 58.49 µM). Considering both of the activity and cytotoxicity, 
compound 1bh which holds the highest selective index (SI = 4.70) among these analogues could 
be selected as a lead compound for further modification.  
   To our delight, we observed that compound 9a shows acceptable cytotoxicity (CC50 > 200 
µM) and potent anti-ZIKV activity (IC50 = 29.98 µM), suggesting compound 9a might be a potent 
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candidate for further development. Compounds 9b and 11b with higher cytotoxicity (CC50 = 
29.39-70.61 µM) deserve further modification in the future.  
3. Conclusion 
  In summary, the natural product SIN was selected as our lead compound but proved to be 
inactive in this study, whereas its structural analogue EPZ004777 displays considerable 
anti-ZIKV activity (IC50 = 35.19 µM). A series of structural unique SIN derivatives with a 
3-fluoro or chloro-benzyl group and a lipophilicity side chain were designed, synthesized and 
evaluated for anti-ZIKV activity. SIN derivatives 1ad-af, 1ba-bb, and 1bf-bh show more potent 
activity (IC50 = 4.56-20.16 µM) than EPZ004777, but their CC50 values are lower than 
EPZ004777 (CC50 > 200 µM). We also observed that intermediates 9a-b and 11b display potent 
anti-ZIKV activity (IC50 = 6.33-29.98 µM). These intermediates, possessing a simplified structure, 
could be selected as new lead compounds for further studies. In addition, we found that 
compound 9a displays acceptable cytotoxicity (CC50 > 200 µM), suggesting its promising 
potential as a candidate for further development. Studies to determine the in vivo efficacy of 9a 
are currently underway. 
Table 2. Anti-ZIKV activity and cytotoxicity of compounds 9-12 
Compds. IC50 (µM)   CC50 (µM)   SI 
9a 29.98 ± 6.93 >200 >6.67 
9b 6.33 ± 1.93 29.39±8.55 4.64 
10a >50 ND NA 
10b >50 ND NA 
11a >50 ND NA 
11b 27.47 ± 4.32 70.61±0.05 2.57 
12a >50 ND NA 
12b >50 ND NA 
SIN >50 ND NA 
EPZ004777 35.19 >200  >5.68 
               ND, not detected; NA, not available. 
4. Experimental protocols 
4.1. Chemistry 
1H NMR spectra were determined on a Varian Mercury-400 or Bruker 500 M spectrometer in 
MeOD or CDCl3 using tetramethylsilane as an internal standard. Electrospray ionization (ESI) 
mass spectra was obtained on an Agilent 1260-6420 Mass spectrum instruments. The reagents 
were all of analytical grade or chemically pure. TLC was performed on silica gel plates (Merck, 
ART5554 60F254). All the anhydrous solvents were purchased from J&K Scientific. 
4.2. Synthesis 
4.2.1. ((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyl 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 3a 
   To a stirred solution of compound 2 (3 g, 9.2 mmol) in EtOH (50 mL) was added Et3N (2.6 
mL, 18.4 mmol) and 3-fluorobenzylamine (2.1 mL, 18.4 mmol) at room temperature. The 
mixture was stirred for 5 hours at 40 oC and concentrated. The residue was purified by column 
chromatography over silica gel (DCM : MeOH : NH3H2O = 200 : 10 : 0.1) to yield compound 3a 
(3.13 g, 82%) as a colorless oil; [α]20D = -167.77 (c 0.78, MeOH);  1H NMR (500 MHz, CDCl3) δ 
8.39 (s, 1H, purin-H), 7.79 (s, 1H, purin-H), 7.35-7.30 (m, 1H, Ar-H), 7.17 (d, J = 7.5 Hz, 1H, 
Ar-H), 7.11 (d, J = 9 Hz, 1H, Ar-H), 6.59 (brs, 1H, NH), 5.89 (s, 1H, tetrahydrofuro-H), 5.24 (t, J 
= 5.1 Hz, 1H, tetrahydrofuro-H), 5.14 (d, J = 5.5 Hz, 1H, tetrahydrofuro-H), 4.89 (brs, 2H, 
benzyl-CH2), 4.58 (s, 1H, tetrahydrofuro-H), 4.00 (d, J = 12.6 Hz, 1H, CH2OH-CH), 3.84 (d, J = 
12.6 Hz, 1H, CH2OH-CH), 1.68 (s, 3H, CH3), 1.42 (s, 3H, CH3); 13C NMR (400 MHz, CDCl3) δ 
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162.5 (d, J = 242.6 Hz, Ar-C), 154.8 (purin-C), 152.8  (purin-C), 147.5 (purin-C), 140.7 
(purin-C), 139.8 (Ar-C), 130.2 (d, J = 8.1 Hz, Ar-C), 123.12 (d, J = 2.5 Hz, Ar-H), 121.2 
(purin-C), 114.5 (d, J = 21.8 Hz, Ar-C), 114.0 (Ar-C), 94.4 (tetrahydrofuro-C), 86.1 
(tetrahydrofuro-C), 83.1 (tetrahydrofuro-C), 81.7 (tetrahydrofuro-C), 63.4 (CH2-C), 43.8 
(benzyl-CH2-C), 27.6 (CH3), 25.2 (CH3); LRMS (ESI): m/z = 438 [M + Na]+.   
   
4.2.2. ((3aR,4R,6R,6aR)-6-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyl 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 3b 
   Following above synthetic procedure of compound 3a, replacing 3-fluorobenzylamine with 
3-chlorobenzyamine afforded compound 3b (85%) as a colorless oil, [α]20D = -59.03 (c 0.93, 
MeOH); 1H NMR (500 MHz, CDCl3) δ 8.40 (s, 1H, purin-H), 7.79 (s, 1H, purin-H), 7.39 (s, 1H, 
Ar-H), 7.30-7.28 (m, 3H, Ar-H), 6.59 (brs, 1H, NH), 5.89 (s, 1H, tetrahydrofuro-H), 5.24 (t, J = 
5.1 Hz, 1H, tetrahydrofuro-H), 5.14 (d, J = 5.5 Hz, 1H, tetrahydrofuro-H), 4.89 (brs, 2H, 
benzyl-CH2), 4.58 (s, 1H), 4.00 (d, J = 12.6 Hz, 1H, CH2OH-CH), 3.84 (d, J = 12.6 Hz, 1H, 
CH2OH-CH), 1.68 (s, 3H, CH3), 1.42 (s, 3H, CH3); LRMS (ESI): m/z = 454 [M + Na]+.      
  
4.2.3. 
9-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-N-(3-fl
uorobenzyl)-9H-purin-6-amine 4a 
   To a stirred solution of compound 3a (1 g, 2.4 mmol) in THF (20 mL) was added Ph3P (1.26 
g, 4.8 mmol), DIAD (0.94 mL, 4.8 mmol) and phthalimide (0.53 g, 3.6 mmol) at room 
temperature. The mixture was stirred for 3 hours and concentrated. The residue was purified by 
column chromatography over silica gel (DCM : MeOH : NH3H2O = 200 : 10 : 0.1) to yield a 
brown oil, which was used directly for the next step. 
  To a stirred solution of above oil in EtOH (50 mL) was added hydrazine hydrate (1 mL) at 
room temperature. The mixture was refluxed for 2 hours and filtered. The filtrate was 
concentrated. The residue was purified by column chromatography over silica gel (DCM : 
MeOH : NH3H2O = 100 : 10 : 0.2) to yield compound 4a (680 mg, 68%) as a colorless oil, 1H 
NMR (500 MHz, CDCl3) δ 8.44 (s, 1H, purin-H), 7.88 (s, 1H, purin-H), 7.35-7.30 (m, 1H, Ar-H), 
7.19 (d, J = 7.5 Hz, 1H, Ar-H), 7.12 (d, J = 8.2 Hz, 1H, Ar-H), 7.0 (t, J = 5.1 Hz, 1H, Ar-H), 6.34 
(brs, 1H, NH), 6.04 (d, J = 2.6 Hz, 1H, tetrahydrofuro-H), 5.48-5.46 (m, 1H, tetrahydrofuro-H), 
5.16-5.14 (m, 1H, tetrahydrofuro-H), 4.91 (brs, 2H, benzyl-CH2), 4.36 (brs, 1H, 
tetrahydrofuro-H), 3.16-3.10 (m, 2H, CH2), 1.64 (s, 3H, CH3), 1.40 (s, 3H, CH3); 13C NMR (400 
MHz, CDCl3) δ 162.5 (d, J = 242.5 Hz, Ar-C), 154.7 (purin-C), 153.2 (purin-C), 141.1 (d, J = 7.1 
Hz, Ar-C), 140.0 (purin-C), 139.41 (purin-C), 130.1 (d, J = 8.2 Hz), 123.1 (d, J = 2.7 Hz, Ar-C), 
120.5 (purin-C), 114.7 (acetonide-C), 114.5 (d, J = 21.6 Hz, Ar-C), 114.4 (d, J = 21.5 Hz, Ar-C), 
91.2 (tetrahydrofuro-C), 86.1 (tetrahydrofuro-C), 83.5 (tetrahydrofuro-C), 81.6 (tetrahydrofuro-C), 
43.3 (CH2-C), 41.8 (benzyl-CH2-C), 27.2 (CH3-C), 25.3 (CH3-C); LRMS (ESI): m/z = 415 [M + 
H]+.   
 
4.2.4. 
9-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-N-(3-c
hlorobenzyl)-9H-purin-6-amine 4b 
   Following above synthetic procedure of compound 4a, replacing 3a with 3b afforded 
compound 4b (75%) as a colorless oil, [α]20D = -23.43 (c 1.05, MeOH); 1H NMR (500 MHz, 
CDCl3) δ 8.44 (s, 1H, purin-H), 7.88 (s, 1H, purin-H), 7.40 (s, 1H, Ar-H), 7.35-7.30 (m, 3H, 
Ar-H), 6.34 (brs, 1H, NH), 6.06 (d, J = 2.6 Hz, 1H, tetrahydrofuro-H), 5.48-5.46 (m, 1H, 
tetrahydrofuro-H), 5.16-5.14 (m, 1H, tetrahydrofuro-H), 4.91 (brs, 2H, benzyl-CH2), 4.30 (brs, 
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1H, tetrahydrofuro-H), 3.10-2.99 (m, 2H, CH2), 1.64 (s, 3H, CH3), 1.43 (s, 3H, CH3); LRMS 
(ESI): m/z = 431 [M + H]+.  
      
4.2.5. N-(3-fluorobenzyl)-9-((3aR,4R,6R,6aR)-6-((isopropylamino)methyl)-2,2-dimethyl 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine 5a 
   To a stirred solution of compound 4a (1 g, 2.4 mmol) in MeOH (30 mL) was added acetone 
(3 mL) and NaCNBH3 (0.6 g, 9.6 mmol) at room temperature. The mixture was stirred for 15 
minutes, adjusted to pH 7 by acetic acid. The mixture was stirred 4 hours at the same temperature, 
quenched by 1M NaOH solution (10 mL) at 0 oC, diluted by H2O (50 mL), and extracted by 
DCM (30 mL × 3). The organic layer was washed by brine, dried over anhydrous MgSO4, filtered 
and concentrated. The residue was purified by column chromatography over silica gel (DCM : 
MeOH : NH3H2O = 100 : 10 : 1) to yield compound 5a (850 mg, 77%) as an oil, 1H NMR (500 
MHz, CDCl3) δ 8.43 (s, 1H, purin-H), 7.89 (s, 1H, purin-H), 7.35-7.30 (m, 1H, Ar-H), 7.18 (d, J 
= 7.5 Hz, 1H, Ar-H), 7.12 (d, J = 9.5 Hz, Ar-H), 7.01 (t, J = 7.0 Hz, 1H, Ar-H), 6.48 (brs, 1H, 
NH), 6.05 (s, 1H, tetrahydrofuro-H), 5.51 (brs, 1H, tetrahydrofuro-H), 5.10-5.08 (m, 1H, 
tetrahydrofuro-H), 4.90 (brs, 2H, benzyl-CH2), 4.40 (brs, 1H, tetrahydrofuro-H), 2.98-2.90 (m, 
2H, CH2), 2.80-2.78 (m, 1H, isopropyl-CH), 1.65 (s, 3H, CH3), 1.43 (s, 1H, CH3), 1.08 (d, J = 6.2 
Hz, 3H, isopropyl-CH3), 1.05 (d, J = 6.2 Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, CDCl3) δ 
162.5 (d, J = 242.5 Hz, Ar-C), 154.7 (purin-C), 153.2 (purin-C), 148.6 (purin-C), 141.1 (d, J = 6.8 
Hz, Ar-C), 139.4 (purin-C), 130.1 (d, J = 8.2 Hz, Ar-C), 123.0 (d, J = 2.7 Hz, Ar-C), 120.5 
(purin-C), 114.6 (acetonide-C), 114.5 (d, J = 21.6 Hz, Ar-C), 114.4 (d, J = 21.5 Hz, Ar-C), 90.9 
(tetrahydrofuro-C), 85.7 (tetrahydrofuro-C), 83.5 (tetrahydrofuro-C), 82.2 (tetrahydrofuro-C), 
48.9 (isopropyl-CH-C), 48.8 (CH2-C), 43.9 (benzyl-C), 27.3 (acetonide-CH3-C), 25.4 
(acetonide-CH3-C), 22.7 (isopropyl-CH3-C), 22.6 (isopropyl-CH3-C); LRMS (ESI): m/z = 457 [M 
+ H]+.   
 
4.2.6. N-(3-chlorobenzyl)-9-((3aR,4R,6R,6aR)-6-((isopropylamino)methyl)-2,2-dimethyl 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine 5b 
   Following above synthetic procedure of compound 5a, replacing 4a with 4b afforded 
compound 5b (75%) as an oil, LRMS (ESI): m/z = 473 [M + H]+.    
 
4.2.7. methyl 
3-((((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3
,4-d][1,3]dioxol-4-yl)methyl)(isopropyl)amino)propanoate 6a 
A solution of 5a (1 g, 2.2 mmol) and methyl acrylate (0.4 mL) in MeOH (10 mL) was sealed in a 
microwave tube, heated to 90 oC under microwave radiation for 3 hours. The mixture was 
concentrated and purified by column chromatography over silica gel (DCM : MeOH = 40 : 1) to 
yield compound 6a (0.9 g, 76%) as an oil, 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H, purin-H), 
7.90 (s, 1H, purin-H), 7.35-7.30 (m, 1H, Ar-H), 7.18 (d, J = 7.5 Hz, 1H, Ar-H), 7.12 (d, J = 9.5 
Hz, Ar-H), 7.01 (t, J = 7.0 Hz, 1H, Ar-H), 6.32 (brs, 1H, NH), 6.07 (s, 1H, tetrahydrofuro-H), 
5.57 (brs, 1H, tetrahydrofuro-H), 5.08 (brs, 1H, tetrahydrofuro-H), 4.90 (brs, 2H, benzyl-CH2), 
4.34 (brs, 1H, tetrahydrofuro-H), 3.69 (s, 3H, MeO-CH3), 2.94-2.48 (m, 7H, CH2CH2, CH2, and 
isopropyl-CH), 1.65 (s, 3H, acetonide-CH3), 1.43 (s, 3H, acetonide-CH3), 1.05 (s, 3H, 
isopropyl-CH3), 0.92 (s, 3H, isopropyl-CH3); 13C NMR (400 MHz, CDCl3) δ 162.5 (d, J = 242.5 
Hz, Ar-C), 154.7 (purin-C), 153.2 (purin-C), 148.6 (purin-C), 141.1 (d, J = 6.8 Hz, Ar-C), 139.8 
(purin-C), 130.1 (d, J = 8.2 Hz, Ar-C), 123.0 (d, J = 2.7 Hz, Ar-C), 120.5 (purin-C), 114.5 (d, J = 
21.6 Hz, Ar-C), 114.4 (d, J = 21.5 Hz, Ar-C), 91.2 (tetrahydrofuro-C), 83.6 (tetrahydrofuro-C), 
83.2 (tetrahydrofuro-C), 77.2 (tetrahydrofuro-C), 51.9 (MeO-C), 51.7 (CH2-C), 46.3 (CH2-C), 
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43.8 (benzyl-CH2), 27.1 (acetonide-CH3-C), 25.4 (acetonide-CH3-C), 18.8 (isopropyl-CH3-C), 
16.7 (isopropyl-CH3-C); LRMS (ESI): m/z = 543 [M + H]+. 
 
4.2.8. methyl 
3-((((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3
,4-d][1,3]dioxol-4-yl)methyl)(isopropyl)amino)propanoate 6b 
   Following above synthetic procedure of compound 6a, replacing 5a with 5b afforded 
compound 6b (80%) as an oil, LRMS (ESI): m/z = 559 [M + H]+.       
   
4.2.9.  3-((((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyl 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(isopropyl)amino)propan-1-ol 7a 
   To a stirred solution of 6a (900 mg, 1.66 mmol) in anhydrous THF (10 mL) was added 
LiAlH4 (3.3 mL, 1 N solution in THF) at 0 oC. The mixture was stirred for 1 hour at 0 oC, diluted 
by ether (20 mL), and slowly quenched by H2O (20 µL), NaOH solution (20 µL, 15% solution), 
and H2O (60 µL) succesively. The mixture was stirred for 15 minutes. To the mixture was added 
anhydrous MgSO4, filtered and concentrated. The residue was purified by column 
chromatography over silica gel (DCM : MeOH = 40 : 1) to yield compound 7a (680 mg, 80%) as 
an oil, 1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H, purin-H), 7.92 (s, 1H, purin-H), 7.35-7.30 (m, 
1H, Ar-H), 7.18 (d, J = 7.5 Hz, 1H, Ar-H), 7.12 (d, J = 9.5 Hz, Ar-H), 7.01 (t, J = 7.0 Hz, 1H, 
Ar-H), 6.28 (brs, 1H, NH), 6.12 (s, 1H, tetrahydrofuro-H), 5.54 (brs, 1H, tetrahydrofuro-H), 5.11 
(brs, 1H, tetrahydrofuro-H), 4.92 (brs, 2H, benzyl-CH2), 3.79-3.73 (m, 3H, CH2 and CH), 
3.10-2.78 (m, 4H, CH2CH2), 1.82-1.78 (m, 2H, CH2), 1.66 (s, 3H, acetonide-CH3), 1.43 (s, 3H, 
acetonide-CH3), 1.12 (s, 3H, isopropyl-CH3), 0.87 (s, 3H, isopropyl-CH3); 13C NMR (400 MHz, 
CDCl3) δ 162.5 (d, J = 242.5 Hz, Ar-C), 154.7 (purin-C), 153.2 (purin-C), 148.6 (purin-C), 141.1 
(d, J = 6.8 Hz, Ar-C), 140.1 (purin-C), 130.1 (d, J = 8.2 Hz, Ar-C), 123.0 (d, J = 2.7 Hz, Ar-C), 
120.5 (purin-C), 114.9 (acetonide-C), 114.5 (d, J = 21.6 Hz, Ar-C), 114.4 (d, J = 21.5 Hz, Ar-C), 
90.7 (tetrahydrofuro-C), 83.8 (tetrahydrofuro-C), 83.4 (tetrahydrofuro-C), 77.2 (tetrahydrofuro-C), 
65.6 (tetrahydrofuro-C), 62.7 (CH2OH-C), 51.4 (isopropyl-CH-C), 49.3 (CH2-C), 43.8 
(benzyl-CH2-C), 27.1 (acetonide-CH3-C), 25.4 (acetonide-CH3-C), 17.6 (isopropyl-CH3-C), 15.8 
(isopropyl-CH3-C); LRMS (ESI): m/z = 515 [M + H]+. 
 
4.2.10. 3-((((3aR,4R,6R,6aR)-6-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyl 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(isopropyl)amino)propan-1-ol 7b 
   Following above synthetic procedure of compound 7a, replacing 6a with 6b afforded 
compound 7b (85%) as an oil, LRMS (ESI): m/z = 531 [M + H]+.     
  
4.2.11. 
N1-(((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[
3,4-d][1,3]dioxol-4-yl)methyl)-N1-isopropylpropane-1,3-diamine 8a 
   Following above synthetic procedure of compound 4a, replacing 3a with 7a afforded crude 8a 
(80% percent pure from LC-MS, yield 76%) which was used directly for the next step without 
further purification, LRMS (ESI): m/z = 514 [M + H]+.   
 
4.2.12. 
N1-(((3aR,4R,6R,6aR)-6-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[
3,4-d][1,3]dioxol-4-yl)methyl)-N1-isopropylpropane-1,3-diamine 8b 
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   Following above synthetic procedure of compound 4a, replacing 3a with 7b afforded 8b 
(yield 78%) as an oil which was used directly for the next step without further purification, [α]20D 
= -2.15 (c 1.35, MeOH); 1H NMR (500 MHz, CDCl3) δ 8.41 (s, 1H, purin-H), 8.01 (s, 1H, 
purin-H), 7.37 (s, 1H, Ar-H), 7.30-7.28 (m, 3H, Ar-H), 6.66 (brs, 1H, NH), 6.12 (s, 1H, 
tetrahydrofuran-H), 5.59 (d, J = 5.8 Hz, 1H, tetrahydrofuran-H), 5.05-5.03 (m, 1H, 
tetrahydrofuran-H), 4.87 (brs, 2H, benzyl-CH2), 4.32 (brs, 1H, tetrahydrofuran-H), 2.97-2.95 (m, 
1H, isopropyl-CH), 2.81-2.79 (m, 2H, CH2), 2.68-2.65 (m, 1H, CH2-H), 2.53-2.50 (m, 1H, 
CH2-H), 1.82-1.78 (m, 2H, CH2), 1.59-1.54 (m, 2H, CH2), 1.42 (s, 3H, ), 0.98 (d, J = 6.5 Hz, 3H, 
CH3), 0.78 (d, J = 6.5 Hz, 3H, CH3); LRMS (ESI): m/z = 530 [M + H]+. 
 
4.2.13. General procedure for the synthesis of SIN derivatives 1aa-ah, 1ba-bh. 
   To a stirred solution of 8a-b (0.15 mmol) in acetonitrile (5 mL) was added isocyanate (0.2 
mmol) at room temperature. The mixture was stirred for 1 hour and concentrated. The residue 
was purified by column chromatography over silica gel (DCM : MeOH = 20 : 1) to yield an oil. 
   To a stirred solution of above solid in DCM (6 mL) was added TFA (1 mL) and H2O (0.5 mL) 
at 0 oC. The mixture was stirred overnight and concentrated. The residue was purified by 
preparing TLC (DCM : MeOH : NH3H2O = 70 : 10 : 1) to yield SIN derivatives 1aa-ah, 1ba-bh.  
4.2.13.1. 1-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy 
tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-fluorophenyl)urea 1aa  
   According to the general procedure, employing 8a and 1-fluoro-4- isocyanatobenzene 
afforded compound 1aa as a solid, 80% yield, HPLC purity: 97.6%, method A; mp: 180-182 oC; 
[α]20D = 12.91 (c 0.55, MeOH); 1H NMR (500 MHz, MeOD) δ 8.28 (s, 1H, purin-H), 8.24 (s, 1H, 
purin-H), 7.35-7.29 (m, 3H, Ar-H), 7.22 (d, J = 7.5 Hz, 1H, Ar-H), 7.15 (d, J = 9.8 Hz, 1H, Ar-H), 
7.01-6.95 (m, 3H, Ar-H), 6.02 (d, J = 4.0 Hz, 1H, tetrahydrofuran-H), 4.88 (brs, 2H, benzyl-CH2), 
4.77 (brs, 1H, tetrahydrofuran-H), 4.37-4.35 (m, 1H, tetrahydrofuran-H), 4.25-4.22 (m, 1H, 
tetrahydrofuran-H), 3.28-3.21 (m, 3H, CH2 and isoproyly-CH), 3.08-2.76 (m, 4H, CH2 and CH2), 
1.76-1.73 (m, 2H, CH2), 1.15 (s, 3H, isopropyl-CH3), 1.10 (s, 3H, isopropyl-CH3); 13C NMR (400 
MHz, MeOD) δ 162.1 (d, J = 244.5 Hz, F-phenyl-C), 158.6 (d, J = 240.1 Hz, F-phenyl-C), 156.9 
(urea-C), 154.5 (purin-C), 152.4 (purin-C), 141.9 (purin-C), 139.7 (purin-C), 135.5 
(3-F-phenyl-C), 129.7 (d, J = 8.3 Hz, Ar-C), 129.3 (Ar-C), 122.7 (d, J = 2.8 Hz, Ar-C), 120.6 (d, J 
= 7.7 Hz, Ar-C), 119.6 (purin-C), 114.7 (d, J = 22.6 Hz, 4-F-phenyl-C), 113.6 (d, J = 20.6 Hz, 
3-F-phenyl-C), 113.3 (d, J = 20.3 Hz, 3-F-phenyl-C), 89.2 (tetrahydrofuran-C), 82.7 
(tetrahydrofuran-C), 73.2 (tetrahydrofuran-C), 72.1 (tetrahydrofuran-C), 52.1 (CH2-C), 43.0 
(benzyl-CH2-C), 37.7 (CH2-C), 27.3 (CH2-C), 16.5 (isopropyl-CH3), 16.0 (isopropyl-CH3); 
LRMS (ESI): m/z = 633 [M + Na]+; HRMS-ESI (m/z): Calcd. For C30H37F2N8O4 (M+H)+: 
611.2900; Found: 611.2897. 
 
4.2.13.2. 
1-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofura
n-2-yl)methyl)(isopropyl)amino)propyl)-3-(p-tolyl)urea 1ab 
  According to the general procedure, employing 8a and 1-isocyanato-4-methylbenzene afforded 
compound 1ab as a solid, 76% yield, HPLC purity: 98.9%, method A; mp: 190-192 oC; [α]20D = 
17.36 (c 0.67, MeOH); 1H NMR (500 MHz, MeOD) δ 8.28 (s, 1H, purin-H), 8.20 (s, 1H, 
purin-H), 7.36-7.30 (m, 1H, F-phenyl-H), 7.22-7.18 (m, 3H, Ar-H), 7.13 (d, J = 9.8 Hz, 1H, 
F-phenyl-H), 7.04 (d, J = 7.6 Hz, 1H, tolyl-H), 6.96 (t, J = 7.5 Hz, 1H, F-phenyl-H), 6.02 (d, J = 
4.0 Hz, 1H, tetrahydrofuran-H), 4.88 (brs, 2H, benzyl-CH2), 4.77 (brs, 1H, tetrahydrofuran-H), 
4.41-4.38 (m, 1H, tetrahydrofuran-H), 4.30-4.25 (m, 1H, tetrahydrofuran-H), 3.44-3.41 (m, 1H, 
isopropyl-CH), 3.26-3.20 (m, 4H, CH2 and CH2), 2.92-2.90 (m, 2H, CH2), 2.72 (s, 3H, tolyl-CH3), 
1.82-1.78 (m, 2H, CH2), 1.22 (s, 3H, isopropyl-CH3), 1.17 (s, 3H, isopropyl-CH3); 13C NMR (400 
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MHz, MeOD) δ 162.1 (d, J = 244.5 Hz, F-phenyl-C), 157.3 (urea-C), 154.6 (purin-C), 152.4 
(purin-C), 141.9 (purin-C), 139.8 (purin-C), 136.5 (Me-phenyl-C), 131.7 (Me-phenyl-C), 129.8 (d, 
J = 8.3 Hz, F-phenyl-C), 128.7 (Me-phenyl-C), 122.7 (d, J = 2.8 Hz, F-phenyl-C), 119.8 
(purin-C), 119.1 (Me-phenyl-C), 113.6 (d, J = 22.1 Hz, F-phenyl-C), 113.3 (d, J = 21.9 Hz, 
F-phenyl-C), 89.7 (tetrahydrofuran-C), 81.5 (tetrahydrofuran-C), 73.1 (tetrahydrofuran-C), 72.0 
(tetrahydrofuran-C), 52.0 (CH2-C), 48.3 (CH2-C), 43.0 (benzyl-CH2-C), 37.2 (isopropyl-CH-C), 
26.8 (CH2-C), 16.1 (isopropyl-CH3-C), 15.7 (isopropyl-CH3-C); LRMS (ESI): m/z = 607 [M + 
H]+; HRMS-ESI (m/z): Calcd. For C31H40N8O4F (M+H)+: 607.3151; Found: 607.3129. 
 
4.2.13.3 
1-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofura
n-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-methoxyphenyl)urea 1ac        
  According to the general procedure, employing 8a and 1-isocyanato-4-methoxylbenzene 
afforded compound 1ac as a solid, 79% yield, HPLC purity: 98.4%, method A; mp: 143-144 oC; 
[α]20D = 14.34(c 0.45, MeOH);    1H NMR (500 MHz, CDCl3) δ 8.30 (s, 1H, purin-H), 7.92 (s, 
1H, purin-H), 7.66 (s, 1H, NH), 7.29-7.24 (m, 1H, Ar-H), 7.21 (d, J = 8.5 Hz, 2H, 
MeO-phenyl-H), 7.14 (d, J = 7.5 Hz, 1H, F-phenyl-H), 7.09 (d, J = 9.5 Hz, 1H, F-phenyl-H), 6.95 
(t, J = 7.5 Hz, 1H, F-phenyl-H), 6.75 (d, J = 8.5 Hz, 2H, ,MeO-phenyl-H), 6.66 (brs, 1H, NH), 
6.31 (brs, 1H, NH), 5.95 (d, J = 3.3 Hz, 1H, tetrahydrofuran-H), 4.84 (brs, 2H, benzyl-CH2), 4.65 
(brs, 1H, tetrahydrofuran-H), 4.51 (brs, 1H, tetrahydrofuran-H), 4.32 (brs, 1H, tetrahydrofuran-H), 
3.72 (s, 3H, MeO-CH3), 3.24-3.17 (m, 3H, CH2 and isopropyl-CH), 2.97-2.83 (m, 2H, CH2), 2.67 
(brs, 2H, CH2), 1.69-1.65 (m, 2H, CH2), 1.07 (d, J = 5.6 Hz, 3H, isopropyl-CH3), 0.98 (d, J = 5.6 
Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, CDCl3) δ 162.1 (d, J = 244.5 Hz, F-phenyl-C), 
157.4 (MeO-phenyl-C), 155.8 (urea-C), 154.6 (purin-C), 152.9 (purin-C), 141.2 (purin-C), 139.0 
(purin-C), 131.8 (MeO-phenyl-C), 130.1 (d, J = 8.3 Hz, F-phenyl-C), 123.1 (Ar-C), 122.3 (Ar-C), 
120.1 (purin-C), 114.4 (d, J = 22.3 Hz, F-phenyl-C), 114.3 (MeO-phenyl-C), 114.1 (d, J = 22.0 
Hz, F-phenyl-C), 89.8 (tetrahydrofuran-C), 82.0 (tetrahydrofuran-C), 74.1 (tetrahydrofuran-C), 
72.5 (tetrahydrofuran-C), 55.4 (MeO-CH3), 51.9 (CH2-C), 48.4 (CH2-C), 43.8 (benzyl-CH2-C), 
38.1 (isopropyl-CH-C), 29.7 (CH2-C), 26.8 (CH2-C), 17.9 (isopropyl-CH3-C), 16.2 
(isopropyl-CH3-C); LRMS (ESI): m/z = 645 [M + Na]+; HRMS-ESI (m/z): Calcd. For 
C31H40N8O5F (M+H)+: 623.3100; Found: 623.3078. 
 
4.2.13.4. 
1-(4-(tert-butyl)phenyl)-3-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)urea 1ad 
  According to the general procedure, employing 8a and 1-(tert-butyl)-4-isocyanatobenzene 
afforded compound 1ad as a solid, 72% yield, HPLC purity: 96.5%, method B; mp: 110-112 oC; 
[α]20D = 10.12 (c 0.57, MeOH);   1H NMR (500 MHz, CDCl3) δ 8.32 (s, 1H, purin-H), 7.94 (s, 
1H, purin-H), 7.71 (s, 1H, NH), 7.29-7.24 (m, 5H, Ar-H), 7.14 (d, J = 7.5 Hz, 1H, F-phenyl-H), 
7.09 (d, J = 9.5 Hz, 1H, F-phenyl-H), 6.96 (t, J = 7.5 Hz, 1H, F-phenyl-H), 6.66 (brs, 1H, NH), 
6.36 (brs, 1H, NH), 5.95 (d, J = 3.3 Hz, 1H, tetrahydrofuran-H), 4.85 (brs, 2H, benzyl-CH2), 4.66 
(brs, 1H, tetrahydrofuran-H), 4.54 (brs, 1H, tetrahydrofuran-H), 4.35 (brs, 1H, tetrahydrofuran-H), 
3.27 (brs, 2H, CH2), 3.14-3.10 (m, 1H, isopropyl-CH), 2.97-2.83 (m, 2H, CH2), 2.67 (brs, 2H, 
CH2), 1.71-1.68 (m, 2H, CH2), 1.27 (s, 9H, tBu), 1.07 (d, J = 5.6 Hz, 3H, isopropyl-CH3), 0.98 (d, 
J = 5.6 Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, CDCl3) δ 162.1 (d, J = 244.5 Hz, 
F-phenyl-C), 156.9 (urea-C), 154.6 (purin-C), 152.9 (purin-C), 145.8 (t-Bu-phenyl-C), 141.9 
(purin-C), 139.0 (purin-C), 136.3 (t-Bu-phenyl-C), 130.1 (d, J = 8.3 Hz, F-phenyl-C), 125.8 
(t-Bu-phenyl-C), 123.1 (d, J = 2.8 Hz, F-phenyl-C), 120.1 (purin-C), 119.5 (t-Bu-phenyl-C), 
114.5 (d, J = 21.6 Hz, F-phenyl-C), 114.2 (d, J = 20.8 Hz, F-phenyl-C), 89.8 (tetrahydrofuran-C), 
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82.3 (tetrahydrofuran-C), 74.2 (tetrahydrofuran-C), 72.6 (tetrahydrofuran-C), 52.0 (CH2-C), 50.7 
(CH2-C), 48.5 (isopropyl-CH-C), 43.8 (benzyl-CH2-C), 38.2 (CH2-C), 34.2 (t-Bu-C), 31.3 
(t-Bu-CH3-C), 26.8 (CH2-C), 18.2 (isopropyl-CH3-C), 16.1 (isopropyl-CH3-C); LRMS (ESI): m/z 
= 671 [M + Na]+; HRMS-ESI (m/z): Calcd. For C34H46N8O4F (M+H)+: 649.3621; Found: 
649.3611. 
 
4.2.13.5. 1-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy 
tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(trifluoromethyl)phenyl)urea 1ae 
   According to the general procedure, employing 8a and 
1-isocyanato-4-(trifluoromethyl)benzene afforded compound 1ae as a solid, 85% yield, HPLC 
purity: 95.8%, method B; mp: 119-120oC; [α]20D = 10.73 (c 1.38, MeOH); 1H NMR (500 MHz, 
CDCl3) δ 8.29 (s, 1H, purin-H), 8.19 (brs, 1H, NH), 7.92 (s, 1H, purin-H), 7.45 (d, J = 8.1 Hz, 2H, 
CF3-phenyl-H), 7.40 (d, J = 8.1 Hz, 2H, CF3-phenyl-H), 7.29-7.24 (m, 1H, F-phenyl-H), 7.14 (d, 
J = 7.5 Hz, 1H, F-phenyl-H), 7.09 (d, J = 9.5 Hz, 1H, F-phenyl-H), 6.96 (t, J = 7.5 Hz, 1H, 
F-phenyl-H), 6.69 (brs, 2H, NH and NH), 5.97 (d, J = 3.3 Hz, 1H, tetrahydrofuran-H), 4.83 (brs, 
2H, benzyl-CH2), 4.64 (brs, 1H, tetrahydrofuran-H), 4.49 (brs, 1H, tetrahydrofuran-H), 4.35-4.32 
(m, 1H, tetrahydrofuran-H), 3.27 (brs, 2H, CH2), 3.14-3.10 (m, 1H, isopropyl-CH), 2.97-2.83 (m, 
2H, CH2), 2.67 (brs, 2H, CH2), 1.71-1.68 (m, 2H, CH2), 1.07 (d, J = 5.6 Hz, 3H, isopropyl-CH3), 
0.98 (d, J = 5.6 Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, CDCl3) δ 162.1 (d, J = 244.5 Hz, 
F-phenyl-C), 156.1 (urea-C), 154.6 (purin-C), 152.9 (purin-C), 148.2 (F-phenyl-C), 142.6 
(CF3-phenyl-C), 140.9 (d, J = 6.9 Hz, F-phenyl-C), 138.6 (Ar-C), 130.1 (d, J = 8.2 Hz, Ar-C), 
126.0 (d, J = 3.5 Hz, Ar-C), 124.2 (q, J = 272 Hz, CF3-C), 123.5 (q, J = 32.7 Hz, CF3-phenyl-C), 
123.0 (d, J = 2.8 Hz, Ar-C), 120.04 (Ar-C), 114.5 (Ar-C), 114.2 (Ar-C), 89.8 (tetrahydrofuran-C), 
82.3 (tetrahydrofuran-C), 74.3 (tetrahydrofuran-C), 72.8 (tetrahydrofuran-C), 52.0 (CH2-C), 51.3 
(CH2-C), 43.8 (benzyl-CH2-C), 38.4 (CH2-C), 26.3 (CH2-C), 18.1 (isopropyl-CH3-C), 16.0 
(isopropyl-CH3-C); LRMS (ESI): m/z = 661 [M + H]+; HRMS-ESI (m/z): Calcd. For 
C31H37N8O4F4 (M+H)+: 661.2868; Found: 661.2866. 
     
4.2.13.6. 1-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy 
tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(3-(trifluoromethyl)phenyl)urea 1af 
   According to the general procedure, employing 8a and 
1-isocyanato-3-(trifluoromethyl)benzene afforded compound 1af as an oil, 68% yield, HPLC 
purity: 98.1%, method A; [α]20D = 9.54 (c 0.71, MeOH); 1H NMR (500 MHz, CDCl3) δ 8.29 (s, 
1H, purin-H), 7.96 (s, 1H, NH), 7.78 (s, 1H, purin-H), 7.51 (d, J = 7.8 Hz, 1H, CF3-phenyl-H), 
7.29-7.24 (m, 1H, Ar-H), 7.17-7.14 (m, 2H, Ar-H), 7.09 (d, J = 9.5 Hz, 1H, Ar-H), 6.96 (t, J = 7.5 
Hz, 1H, Ar-H), 6.75 (brs, 1H, NH), 6.50 (brs, 1H, NH), 5.99 (d, J = 3.3 Hz, 1H, 
tetrahydrofuran-H), 4.83 (brs, 2H, benzyl-CH2), 4.65 (brs, 2H, tetrahydrofuran-H), 4.51 (brs, 1H, 
tetrahydrofuran-H), 3.32-2.87 (m, 7H, 3 × CH2 and isopropyl-CH), 1.87 (brs, 2H, CH2), 1.19 (d, J 
= 5.6 Hz, 3H, isopropyl-CH3), 1.07 (d, J = 5.6 Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, 
CDCl3) δ 162.1 (d, J = 244.5 Hz, F-phenyl-C), 156.1 (urea-C), 154.6 (purin-C), 152.9 (purin-C), 
141.0 (purin-C), 140.0 (CF3-phenyl-C), 139.2 (purin-C), 131.0 (q, J = 32.5 Hz, CF3-phenyl-C), 
130.2 (d, J = 8.4 Hz, F-phenyl-C), 129.2 (Ar-C), 123.2 (q, J = 272.1 Hz, CF3-C), 123.1 (Ar-C), 
121.6 (Ar-C), 118.6 (Ar-C), 115.0 (Ar-C), 114.5 (d, J = 21.7 Hz, F-phenyl-C), 114.3 (d, J = 21.5 
Hz, F-phenyl-C), 90.2 (tetrahydrofuran-C), 82.3 (tetrahydrofuran-C), 74.1 (tetrahydrofuran-C), 
72.5 (tetrahydrofuran-C), 52.0 (CH2-C), 48.9 (CH2-C), 43.2 (benzyl-CH2-C), 37.6 (CH2-C), 26.0 
(CH2-C), 17.7 (isopropyl-CH3-C), 15.9 (isopropyl-CH3-C); LRMS (ESI): m/z = 661 [M + Na]+; 
HRMS-ESI (m/z): Calcd. For C31H37N8O4F4 (M+H)+: 661.2868; Found: 661.2867. 
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4.2.13.7. 
1-(tert-butyl)-3-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxyt
etrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)urea 1ag 
  According to the general procedure, employing 8a and 2-isocyanato-2-methylpropane afforded 
compound 1ag as an oil, 73% yield, HPLC purity: 97.2%, method A; [α]20D = 1.43 (c 0.77, 
MeOH); 1H NMR (500 MHz, CDCl3) δ 8.37 (s, 1H, purin-H), 7.97 (s, 1H, purin-H), 7.29-7.24 (m, 
1H, Ar-H), 7.14 (d, J = 7.5 Hz, 1H, Ar-H), 7.09 (d, J = 9.5 Hz, 1H, Ar-H), 6.96 (t, J = 7.5 Hz, 1H, 
Ar-H), 6.52 (brs, 1H, NH), 5.99 (d, J = 3.3 Hz, 1H, tetrahydrofuran-H), 4.89 (brs, 2H, 
benzyl-CH2), 4.74 (brs, 1H, tetrahydrofuran-H), 4.60 (brs, 1H, tetrahydrofuran-H), 4.35-4.32 (m, 
1H, tetrahydrofuran-H), 3.27 (brs, 2H, CH2), 3.14-3.10 (m, 1H, isopropyl-CH), 3.04-2.86 (m, 2H, 
CH2), 2.72 (brs, 2H, CH2), 1.75-1.72 (m, 2H, CH2), 1.32 (s, 9H, t-Bu), 1.16 (d, J = 5.6 Hz, 3H, 
isopropyl-CH3), 1.03 (d, J = 5.6 Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, CDCl3) δ 162.1 (d, 
J = 244.5 Hz, F-phenyl-C), 158.8 (urea-C), 154.6 (purin-C), 152.9 (purin-C), 148.6 (purin-C), 
141.2 (d, J = 6.9 Hz, F-phenyl-C), 139.2 (purin-C), 130.2 (d, J = 8.2 Hz, F-phenyl-C), 123.0 (d, J 
= 2.8 Hz, F-phenyl-C), 120.3 (purin-C), 114.5 (d, J = 21.7 Hz, F-phenyl-C), 114.3 (d, J = 21.8 Hz, 
F-phenyl-C), 90.0 (tetrahydrofuran-C), 82.6 (tetrahydrofuran-C), 74.0 (tetrahydrofuran-C), 72.3 
(tetrahydrofuran-C), 51.8 (CH2-C), 50.3 (t-Bu-C), 48.6 (CH2-C), 43.8 (benzyl-CH2-C), 38.6 
(CH2-C), 29.7 (t-Bu-CH3-C), 26.7 (CH2-C), 18.6 (isopropyl-CH3-C), 15.8 (isopropyl-CH3-C); 
LRMS (ESI): m/z = 573 [M + H]+; HRMS-ESI (m/z): Calcd. For C28H42N8O4F (M+H)+: 573.3308; 
Found: 573.3317. 
 
4.2.13.8. 
1-cyclohexyl-3-(3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxyt
etrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)urea 1ah 
  According to the general procedure, employing 8a and 1-isocyanato-4-methoxylbenzene 
afforded compound 1ah as an oil, 76% yield, HPLC purity: 96.8%, method B; [α]20D = 5.05 (c 
0.69, MeOH); 1H NMR (500 MHz, MeOD) δ 8.31 (s, 1H, purin-H), 8.25 (s, 1H, purin-H), 
7.40-7.34 (m, 1H, Ar-H), 7.20 (d, J = 7.5 Hz, 1H, Ar-H), 7.15 (d, J = 9.5 Hz, 1H, Ar-H), 7.00 (t, J 
= 7.5 Hz, 1H, Ar-H), 6.04 (d, J = 4.0 Hz, 1H, tetrahydrofuran-H), 4.88 (brs, 2H, benzyl-CH2), 
4.79 (brs, 1H, tetrahydrofuran-H), 4.37 (brs, 1H, tetrahydrofuran-H), 4.23 (brs, 2H, 
etrahydrofuran-H), 0.98 (brs, 1H, isopropyl-CH), 3.46-3.43 (m, 1H, cyclohexyl-H), 3.24-2.72 (m, 
7H, cyclohexyl-CH-H and 3 × CH2), 1.85-1.61 (m, 8H, CH2 and cyclohexyl-6H), 1.23-1.10 (m, 
10H, 2 × CH3 and cyclohexyl-4H); 13C NMR (400 MHz, MeOD) δ 162.1 (d, J = 244.5 Hz, Ar-H), 
159.1 (urea-C), 154.6 (purin-C), 152.5 (purin-C), 142.0 (Ar-C), 139.8 (purin-C), 129.7 (d, J = 8.2 
Hz, Ar-C), 122.7 (d, J = 2.8 Hz, Ar-C), 119.7 (purin-C), 113.5 (d, J = 22.2 Hz, Ar-C), 113.3 (d, J 
= 22.4 Hz, Ar-C), 89.2 (tetrahydrofuran-C), 82.7 (tetrahydrofuran-C), 73.1 (tetrahydrofuran-C), 
72.0 (tetrahydrofuran-C), 52.0 (CH2-C), 48.5 (CH2-C), 43.2 (benzyl-CH2-C), 37.5 (CH2-C), 33.2 
(cyclohexyl-CH2-C), 26.6 (CH2-C), 25.4 (cyclohexyl-CH2-C), 25.2 (cyclohexyl-CH2-C), 16.7 
(isopropyl-CH3-C), 15.8 (isopropyl-CH3-C); LRMS (ESI): m/z = 599 [M + Na]+; HRMS-ESI 
(m/z): Calcd. For C30H44N8O4F4 (M+H)+: 599.3464; Found: 599.3464. 
   
4.2.13.9. 
1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofura
n-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-fluorophenyl)urea 1ba 
   According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene 
afforded compound 1ba as a solid, 75% yield, HPLC purity: 99.6%, method A; mp: 189-191oC; 
[α]20D = -25.34 (c 0.23, DMSO); 1H NMR (500 MHz, DMSO-d6) δ 8.47 (brs, 1H, purin-H), 8.43 
(s, 1H, NH), 8.22 (s, 1H, purin-H), 7.39-7.35 (m, 3H, Ar-H), 7.33-7.25 (m, 3H, Ar-H), 7.06-7.01 
(m, 2H, Ar-H), 6.13 (brs, 1H, NH), 5.88 (d, J = 6.9 Hz, 1H, tetrahydrofuran-H), 5.44 (d, J = 7.4 
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Hz, 1H, tetrahydrofuran-H), 5.18 (d, J = 5.8 Hz, 1H, tetrahydrofuran-H), 4.76-4.70 (m, 3H, 
tetrahydrofuran-H and benzyl-CH2), 4.15 (brs, 1H, CH2-1H), 3.93 (brs, 1H, CH2-1H), 3.08-3.06 
(m, 2H, CH2), 2.98-2.92 (m, 1H, isopropyl-CH), 2.86-2.78 (m, 1H, NH), 2.46-2.40 (m, 2H, CH2), 
1.54-1.50 (m, 2H, CH2), 0.97 (d, J = 6.3 Hz, 3H, isopropyl-CH3), 0.88 (d, J = 6.3 Hz, 3H, 
isopropyl-CH3); 13C NMR (400 MHz, DMSO-d6) δ 157.2 (d, J = 237.5 Hz, F-phenyl-C), 155.7 
(urea-C), 154.7 (purin-C), 152.9 (purin-C), 148.3 (Cl-phenyl-C), 143.2 (purin-C), 140.6 (purin-C), 
137.4 (F-phenyl-C), 133.3 (Ar-C), 130.5 (Ar-C), 127.3 (Ar-C), 127.0 (Ar-C), 126.2 (Ar-C), 119.6 
(d, J = 7.4 Hz, F-phenyl-C), 115.6 (Ar-C), 115.3 (Ar-C), 87.8 (tetrahydrofuran-C), 84.3 
(tetrahydrofuran-C), 72.8 (tetrahydrofuran-C), 72.1 (tetrahydrofuran-C), 52.6 (CH2-C), 50.7 
(CH2-C), 48.1 (isopropyl-CH-C), 42.8 (benzyl-CH2-C), 37.8 (CH2-C), 29.4 (CH2-C), 19.4 
(isopropyl-CH3-C), 17.1 (isopropyl-CH3-C); LRMS (ESI): m/z = 627 [M + H]+; HRMS-ESI 
(m/z): Calcd. For C30H37N8O4FCl (M+H)+: 627.2605; Found: 627.2622. 
 
4.2.13.10. 
1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofura
n-2-yl)methyl)(isopropyl)amino)propyl)-3-(p-tolyl)urea 1bb 
  According to the general procedure, employing 8b and 1-isocyanato-4-methylbenzene afforded 
compound 1bb as a solid, 65% yield, HPLC purity: 92.0%, method A; mp: 180-181oC; [α]20D = 
13.69 (c 0.45, MeOH); 1H NMR (500 MHz, MeOD) δ 8.30 (s, 1H, purin-H), 8.18 (s, 1H, 
purin-H), 7.41 (s, 1H, Ar-H), 7.33-7.28 (m, 3H, Ar-H), 7.20 (d, J = 8.8 Hz, 2H, Me-phenyl-H), 
7.05 (d, J = 8.8 Hz, 2H, Me-phenyl-H), 6.01 (d, J = 4.0 Hz, 1H, tetrahydrofuran-H), 4.79 (brs, 2H, 
benzyl-CH2), 4.78-4.76 (m, 1H, tetrahydrofuran-H), 4.49 (brs, 1H, tetrahydrofuran-H), 4.40 (brs, 
1H, tetrahydrofuran-H), 3.38-3.35 (m, 3H, CH2 and isopropyl-CH), 3.28-3.17 (m, 4H, 2 × CH2), 
2.28 (s, 3H, tolyl-CH3), 1.92 (brs, 2H, CH2), 1.29 (s, 3H, isopropyl-CH3), 0.94 (s, 3H, 
isopropyl-CH3); 13C NMR (400 MHz, MeOD) δ 157.4 (urea-C), 152.5 (purin-C), 141.5 (Ar-C), 
140.0 (purin-C), 136.4 (purin-C), 133.9 (Ar-C), 131.9 (Ar-C), 129.5 (Ar-C), 129.3 (Ar-C), 128.8 
(Ar-C), 128.4 (Ar-C), 126.9 (Ar-C), 126.7 (Ar-C), 125.3 (Ar-C), 119.2 (Ar-C), 90.2 
(tetrahydrofuran-C), 80.2 (tetrahydrofuran-C), 72.9 (tetrahydrofuran-C), 72.1 (tetrahydrofuran-C), 
51.9 (CH2-C), 48.6 (CH2-C), 42.9 (benzyl-C), 26.6 (CH2-C), 22.2 (isopropyl-CH3-C), 19.3 
(isopropyl-CH3-C); LRMS (ESI): m/z = 623 [M + H]+; HRMS-ESI (m/z): Calcd. For 
C31H40N8O4Cl (M+H)+: 623.2856; Found: 623.2858. 
 
4.2.13.11.  1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy 
tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-methoxyphenyl)urea 1bc 
   According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene 
afforded compound 1bc as a solid, 77% yield, HPLC purity: 93.6%, method A; mp: 170-171oC; 
[α]20D = 10.88 (c 0.38, MeOH); 1H NMR (500 MHz, MeOD) δ 8.29 (s, 1H, purin-H), 8.22 (s, 1H, 
purin-H), 7.41 (s, 1H, Ar-H), 7.33-7.28 (m, 3H, Ar-H), 7.20 (d, J = 8.8 Hz, 2H, MeO-phenyl-H), 
6.84 (d, J = 8.8 Hz, 2H, MeO-phenyl-H), 6.02 (d, J = 4.0 Hz, 1H, tetrahydrofuran-H), 4.79 (brs, 
2H, benzyl-CH2), 4.78-4.76 (m, 1H, tetrahydrofuran-H), 4.49 (brs, 1H, tetrahydrofuran-H), 4.34 
(brs, 1H, tetrahydrofuran-H), 3.79 (s, 3H, MeO-CH3), 3.38-3.35 (m, 3H, CH2 and isopropyl-CH), 
3.28-3.17 (m, 4H, 2 × CH2), 1.84 (brs, 2H, CH2), 1.29 (s, 3H, isopropyl-CH3), 0.94 (s, 3H, 
isopropyl-CH3); 13C NMR (400 MHz, MeOD) 157.7 (Meo-phenyl-C), 155.7 (urea-C), 152.5 
(purin-C), 141.5 (purin-C), 139.9 (purin-C), 131.8 (Cl-phenyl-C), 129.5 (Cl-phenyl-C), 129.3 
(purin-C), 126.9 (MeO-phenyl-C), 126.7 (MeO-phenyl-C), 125.3 (Cl-phenyl-C), 121.4 
(Cl-phenyl-C), 113.6 (MeO-phenyl-C), 89.9 (tetrahydrofuran-C), 73.0 (tetrahydrofuran-C), 72.1 
(tetrahydrofuran-C), 54.4 (CH2-C), 51.9 (CH2-C), 48.5 (isopropyl-CH-C), 42.9 (benzyl-CH2-C), 
31.6 (CH2-C), 26.6 (CH2-C), 25.4 (isopropyl-CH3-C), 22.3 (isopropyl-CH3-C); LRMS (ESI): m/z 
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= 639 [M + H]+; HRMS-ESI (m/z): Calcd. For C31H40N8O5Cl (M+H)+: 639.2805; Found: 
639.2812. 
 
4.2.13.12. 
1-(4-(tert-butyl)phenyl)-3-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)urea 1bd 
   According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene 
afforded compound 1bd as a solid, 73% yield, HPLC purity: 99.3%, method A; mp: 122-124oC; 
[α]20D = 12.72 (c 0.78, MeOH); 1H NMR (500 MHz, MeOD) δ 8.27 (s, 1H, purin-H), 8.25 (s, 1H, 
purin-H), 7.41 (s, 1H, Cl-phenyl-H), 7.32-7.22 (m, 7H, Ar-H), 6.02 (d, J = 4.0 Hz, 1H, 
tetrahydrofuran-H), 4.8 (brs, 2H, benzyl-CH2), 4.79-4.76 (m, 1H, tetrahydrofuran-H), 4.35-4.32 
(m, 1H, tetrahydrofuran-H), 4.22-4.18 (m, 1H, tetrahydrofuran-H), 3.29-3.20 (m, 2H, CH2), 3.09 
(brs, 1H, isopropyl-CH), 2.96 (d, J = 12.9 Hz, 1H, CH2-1H), 2.79 (brs, 1H, CH2-1H), 2.62 (brs, 
2H, CH2), 1.70-1.68 (m, 2H, CH2), 1.07 (d, J = 5.7 Hz, 3H, isopropyl-CH3), 1.02 (d, J = 5.7 Hz, 
3H, isopropyl-CH3); 13C NMR (400 MHz, MeOD) 157.0 (urea-C), 152.4 (purin-C), 144.9 
(Cl-phenyl-C), 141.4 (purin-C), 139.6 (purin-C), 136.6 (t-Bu-phenyl-C), 133.9 (Cl-phenyl-C), 
129.5 (Cl-phenyl-C), 126.9 (Cl-phenyl-C), 126.7 (Cl-phenyl-C), 125.3 (Cl-phenyl-C), 125.0 
(t-Bu-phenyl-C), 118.8 (t-Bu-phenyl-C), 89.0 (tetrahydrofuran-C), 83.2 (tetrahydrofuran-C), 73.2 
(tetrahydrofuran-C), 72.0 (tetrahydrofuran-C), 52.1 (CH2-C), 50.6 (CH2-C), 42.9 (benzyl-CH2-C), 
39.0 (CH2-C), 30.4 (t-Bu-CH3-C), 27.8 (CH2-C), 17.0 (isopropyl-CH3-C), 16.2 (isopropyl-CH3-C); 
LRMS (ESI): m/z = 687 [M + Na]+; HRMS-ESI (m/z): Calcd. For C34H46N8O4Cl (M+H)+: 
665.3325; Found: 665.3339. 
 
4.2.13.13. 1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy 
tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(trifluoromethyl)phenyl)urea 1be 
  According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene 
afforded compound 1be as a solid, 80% yield, HPLC purity: 97.6%, method B; mp: 116-117oC; 
[α]20D = 11.53 (c 0.76, MeOH); 1H NMR (500 MHz, MeOD) δ 8.25 (s, 2H, purin-H), 7.52-7.48 
(m, 4H, CF3-phenyl-H), 7.41 (s, 1H, Cl-phenyl-H), 7.33-7.27 (m, 3H, Cl-phenyl-H), 6.02 (d, J = 
4.0 Hz, 1H, tetrahydrofuran-H), 4.88 (brs, 2H, benzyl-CH2), 4.79-4.76 (m, 1H, 
tetrahydrofuran-H), 4.35-4.32 (m, 1H, tetrahydrofuran-H), 4.22-4.18 (m, 1H, tetrahydrofuran-H), 
3.30-3.20 (m, 2H, CH2), 3.09 (brs, 1H, isopropyl-CH), 2.96 (d, J = 12.9 Hz, 1H, CH2-1H), 2.79 
(brs, 1H, CH2-1H), 2.62 (brs, 2H, CH2), 1.70-1.68 (m, 2H, CH2), 1.08 (d, J = 5.7 Hz, 3H, 
isopropyl-CH3), 1.04 (d, J = 5.7 Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, MeOD) 156.1 
(urea-C), 154.5 (purin-C), 152.4 (purin-C), 148.5 (Cl-phenyl-C), 143.3 (purin-C), 141.4 (purin-C), 
139.5 (CF3-phenyl-C), 133.9 (Cl-phenyl-C), 129.5 (Cl-phenyl-C), 126.9 (Cl-phenyl-C), 126.7 
(Cl-phenyl-C), 125.4 (q, J = 3.8 Hz, CF3-phenyl-C), 125.3 (CF3-phenyl-C), 124.5 (q, J =273 Hz, 
CF3-C), 12.9 (q, J = 32.3 Hz, CF3-phenyl-C), 119.6 (purin-C), 117.5 (CF3-phenyl-C), 89.0 
(tetrahydrofuran-C), 83.1 (tetrahydrofuran-C), 73.2 (tetrahydrofuran-C), 72.1 (tetrahydrofuran-C), 
52.2 (CH2-C), 50.6 (CH2-C), 42.9 (benzyl-CH2-C), 38.0 (CH2-C), 27.5 (CH2-C), 16.8 
(isopropyl-CH3-C), 16.2 (isopropyl-CH3-C); LRMS (ESI): m/z = 699 [M + Na]+; HRMS-ESI 
(m/z): Calcd. For C31H37N8O4F3Cl (M+H)+: 677.2573; Found: 677.2585.  
 
4.2.13.14. 1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy 
tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(3-(trifluoromethyl)phenyl)urea 1bf 
 According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene 
afforded compound 1bf as a foam solid, 74% yield, HPLC purity: 98.2%, method B; [α]20D 
=10.00 (c 0.53, MeOH); 1H NMR (500 MHz, MeOD) δ 8.27 (s, 1H, purin-H), 8.25 (s, 1H, 
purin-H), 7.48 (d, J = 2.9 Hz, 1H, Ar-H), 7.42 (s, 1H, Cl-phenyl-H), 7.38 (t, J = 7.8 Hz, 1H, 
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Ar-H), 7.33-7.30 (m, 2H, Ar-H), 7.28 (brs, 1H, Ar-H), 7.21 (d, J = 7.3 Hz, 1H, Ar-H), 6.02 (d, J = 
4.0 Hz, 1H, tetrahydrofuran-H), 4.88 (brs, 2H, benzyl-CH2), 4.79-4.76 (m, 1H, 
tetrahydrofuran-H), 4.35-4.32 (m, 1H, tetrahydrofuran-H), 4.22-4.18 (m, 1H, tetrahydrofuran-H), 
3.30-3.20 (m, 2H, CH2), 3.13 (brs, 1H, isopropyl-CH), 2.96 (d, J = 12.9 Hz, 1H, CH2-1H), 2.84 
(brs, 1H, CH2-1H), 2.66 (brs, 2H, CH2), 1.74-1.70 (m, 2H, CH2), 1.10 (d, J = 5.7 Hz, 3H, 
isopropyl-CH3), 1.05 (d, J = 5.7 Hz, 3H, isopropyl-CH3); 13C NMR (400 MHz, MeOD) 156.3 
(urea-C), 154.5 (purin-C), 152.4 (purin-C), 141.4 (purin-C), 140.5 (CF3-phenyl-C), 139.6 
(purin-C), 133.9 (Cl-phenyl-C), 130.5 (q, J = 31.8 Hz, CF3-phenyl-C), 129.5 (Cl-phenyl-C), 128.9 
(Cl-phenyl-C), 126.9 (Cl-phenyl-C), 126.7 (Cl-phenyl-C), 125.3 (CF3-phenyl-C), 124.2 (q, J = 
274.3 Hz, CF3-C), 121.3 (CF3-phenyl-C), 119.6 (purin-C), 117.3 (q, J = 3.5 Hz, CF3-phenyl-C), 
114.5 (q, J = 3.9 Hz, CF3-phenyl-C), 89.0 (tetrahydrofuran-C), 83.0 (tetrahydrofuran-C), 73.2 
(tetrahydrofuran-C), 72.1 (tetrahydrofuran-C), 52.2 (CH2-C), 50.7 (CH2-C), 42.9 (benzyl-CH2-C), 
37.9 (CH2-C), 27.5 (CH2-C), 16.8 (isopropyl-CH3-C), 16.1 (isopropyl-CH3-C); LRMS (ESI): m/z 
= 677 [M + H]+; HRMS-ESI (m/z): Calcd. For C31H37N8O4F3Cl (M+H)+: 677.2573; Found: 
677.2581. 
 
4.2.13.15. 
1-(tert-butyl)-3-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy
tetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)urea 1bg 
  According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene 
afforded compound 1bg as a foam solid, 76% yield, HPLC purity: 94.7%, method A; [α]20D = 
7.04 (c 0.54, MeOH); 1H NMR (500 MHz, MeOD) δ 8.31 (s, 1H, purin-H), 8.28 (s, 1H, purin-H), 
7.43 (s, 1H, Ar-H), 7.35-7.30 (m, 2H, Ar-H), 7.28-7.25 (m, 1H, Ar-H), 6.04 (d, J = 4.0 Hz, 1H, 
tetrahydrofuran-H), 4.88 (brs, 2H, benzyl-CH2), 4.81-4.80 (m, 1H, tetrahydrofuran-H), 4.38-4.35 
(m, 1H, tetrahydrofuran-H), 4.22-4.18 (m, 1H, tetrahydrofuran-H), 3.30-3.20 (m, 1H, 
isopropyl-CH), 3.13 (t, J = 6.1 Hz, 2H, CH2), 3.10-2.98 (m, 2H, CH2), 2.72 (brs, 2H, CH2), 1.69 
(brs, 2H, CH2), 1.29 (s, 9H, t-Bu), 1.14 (d, J = 5.7 Hz, 3H, isopropyl-CH3), 1.08 (d, J = 5.7 Hz, 
3H, iso`propyl-CH3); 13C NMR (400 MHz, MeOD) 159.1 (urea-C), 154.5 (purin-C), 152.4 
(purin-C), 141.5 (purin-C), 139.1 (purin-C), 133.9 (Ar-C), 129.5 (Ar-C), 127.0 (Ar-C), 126.7 
(Ar-C), 125.3 (Ar-C), 119.7 (purin-C), 89.2 (tetrahydrofuran-C), 82.5 (tetrahydrofuran-C), 73.1 
(tetrahydrofuran-C), 72.0 (tetrahydrofuran-C), 52.0 (CH2-C), 49.3 (CH2-C), 42.9 (benzyl-CH2-C), 
37.2 (CH2-C), 28.3 (t-Bu-CH3-C), 27.6(CH2-C), 16.7 (isopropyl-CH3-C), 15.8 (isopropyl-CH3-C); 
LRMS (ESI): m/z = 589 [M + H]+; HRMS-ESI (m/z): Calcd. For C28H42N8O4Cl (M+H)+: 
589.3012; Found: 589.3039. 
 
4.2.13.16. 
1-(3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofura
n-2-yl)methyl)(isopropyl)amino)propyl)-3-cyclohexylurea 1bh 
 According to the general procedure, employing 8b and 1-isocyanato-4-methoxylbenzene 
afforded compound 1bh as a solid, 68% yield, HPLC purity: 97.3%, method A; mp: 145-147oC; 
[α]20D = 4.71 (c 0.51, MeOH); 1H NMR (500 MHz, MeOD) δ 8.31 (s, 1H, purin-H), 8.28 (s, 1H, 
purin-H), 7.43 (s, 1H, Ar-H), 7.35-7.30 (m, 2H, Ar-H), 7.28-7.25 (m, 1H, Ar-H), 6.04 (d, J = 4.0 
Hz, 1H, tetrahydrofuran-H), 4.88 (brs, 2H, benzyl-CH2), 4.81-4.80 (m, 1H, tetrahydrofuran-H), 
4.38-4.35 (m, 1H, tetrahydrofuran-H), 4.22-4.18 (m, 1H, tetrahydrofuran-H), 3.46-3.42 (m, 1H, 
cyclohexyl-CH), 3.16-3.13 (m, 3H, CH2 and isopropyl-CH), 3.10-2.98 (m, 2H, CH2), 2.69 (brs, 
1H, CH2), 1.86 (brs, 2H, CH2), 1.70-1.60 (m, 6H, 3 × cyclohexyl-CH2), 1.21-1.07 (m, 10H, 2 × 
cyclohexyl-CH2 and 2 × isopropyl-CH3); 13C NMR (400 MHz, MeOD) 159.1 (urea-C), 154.5 
(purin-C), 152.4 (purin-C), 148.6 (Ar-C), 141.5 (purin-C), 139.8 (purin-C), 133.9 (Ar-C), 129.5 
(Ar-C), 126.9 (Ar-C), 126.7 (Ar-C), 125.3 (Ar-C), 119.7 (purin-C), 89.1 (tetrahydrofuran-C), 
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82.8 (tetrahydrofuran-C), 73.1 (tetrahydrofuran-C), 72.0 (tetrahydrofuran-C), 52.0 (CH2-C), 49.8 
(CH2-C), 43.0 (benzyl-CH2-C), 37.5 (CH2-C), 33.2 (cyclohexyl-CH2), 25.2 (cyclohexyl-CH2), 
24.6 (cyclohexyl-CH2), 16.7 (isopropyl-CH3-C), 15.9 (isopropyl-CH3-C); LRMS (ESI): m/z = 
615 [M + H]+; HRMS-ESI (m/z): Calcd. For C30H44N8O4Cl (M+H)+: 615.3169; Found: 615.3186. 
4.2.14. General procedure for the preparation of compounds 9-12 
   To a stirred solution of compound 5-8 in DCM (6 mL) was added TFA (1 mL) and H2O (0.5 
mL) at 0 oC. The mixture was stirred overnight and concentrated. The residue was purified by 
preparing TLC (DCM : MeOH : NH3 H2O = 70 : 10 : 1) to yield compound 9-12.  
 
4.2.14.1. 
(2R,3R,4S,5R)-2-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-5-((isopropylamino)methyl) 
tetrahydrofuran-3,4-diol 9a  
   According to the general procedure, employing 5a afforded compound 9a as a foam solid, 90% 
yield, HPLC purity: 97.8%, method C; [α]20D = -2.55 (c 0.67, MeOH); 1H NMR (500 MHz, 
MeOD) δ 8.30 (s, 1H, purin-H), 8.26 (s, 1H, purin-H), 7.36-7.33 (m, 1H, Ar-H), 7.22 (d, J = 7.5 
Hz, 1H, Ar-H), 7.15 (d, J = 9.8 Hz, 1H, Ar-H), 7.00-6.98 (m, 1H, Ar-H), 6.01 (d, J = 3.8 Hz, 1H, 
tetrahydrofuran-H), 4.85-4.83 (m, 2H, benzyl-CH2), 4.37 (dd, J = 4.2, 4.7 Hz, 1 H, 
tetrahydrofuran-H), 4.28-4.26 (m, 1H, tetrahydrofuran-H), 3.24-3.20 (m, 1H, isopropyl-CH), 
3.15-3.08 (m, 2H, CH2), 1.20-1.18 (m, 6H, isopropyl-CH3); 13C NMR (500 MHz, MeOD) δ 162.8 
(d, J = 245 Hz, Ar-C), 154.7 (purin-C), 152.5 (puirn-C), 142.0 (puirn-C), 140.4 (puirn-C), 129.8 
(Ar-C), 128.7 (Ar-C), 122.7 (d, J = 3 Hz, Ar-C), 120.0 (purin-C), 113.6 (d, J = 21.6 Hz, Ar-C), 
113.3 (d, J = 21.6 Hz, Ar-C), 89.7 (tetrahydrofuran-C), 82.4 (tetrahydrofuran-C), 73.1 
(tetrahydrofuran-C), 72.0 (tetrahydrofuran-C), 49.3 (CH2-C), 48.0 (isopropyl-CH-C), 19.9 
(isopropyl-CH3-C), 19.8 (isopropyl-CH3-C); LRMS (ESI): m/z = 439 [M + Na]+; HRMS-ESI 
(m/z): Calcd. For C20H26N6O3F (M+H)+: 417.2045; Found: 417.2062. 
    
 
4.2.14.2. (2R,3R,4S,5R)-2-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-5-((isopropylamino) 
methyl) tetrahydrofuran-3,4-diol 9b 
   According to the general procedure, employing 5b afforded compound 9b as an oil, 94% 
yield, HPLC purity: 97.9%, method C; [α]20D = -4.13 (c 0.99, MeOH); 1H NMR (500 MHz, 
MeOD) δ 8.30 (s, 1H, purin-H), 8.26 (s, 1H, purin-H), 7.42 (s, 1H, Ar-H), 7.33-7.26 (m, 3H, 
Ar-H), 6.01 (d, J = 3.8 Hz, 1H, tetrahydrofuran-H), 4.85-4.83 (m, 2H, benzyl-CH2), 4.35 (dd, J = 
4.2, 4.7 Hz, 1 H, tetrahydrofuran-H), 4.18-4.16 (m, 1H, tetrahydrofuran-H), 3.20-3.04 (m, 3H, 
CH2 and isopropyl-CH), 1.19-1.17 (m, 6H, isopropyl-CH3); 13C NMR (500 MHz, MeOD) δ 154.6 
(purin-C), 152.5 (purin-C), 141.5 (purin-C), 140.4 (purin-C), 133.9 (Ar-C), 129.6 (Ar-C), 129.4 
(Ar-C), 126.9 (Ar-C), 126.7 (Ar-C), 125.4 (Ar-C), 120.0 (purin-C), 89.7 (tetrahydrofuran-C), 
82.6 (tetrahydrofuran-C), 73.1 (tetrahydrofuran-C), 72.0 (tetrahydrofuran-C), 49.2 (CH2-C), 48.2 
(isopropyl-CH-C), 20.1 (isopropyl-CH3-C); LRMS (ESI): m/z = 433 [M + H]+; HRMS-ESI (m/z): 
Calcd. For C20H26N6O3Cl (M+H)+: 433.1749; Found: 433.1760. 
 
4.2.14.3. methyl 
3-((((2R,3S,4R,5R)-5-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2
-yl)methyl)(isopropyl)amino)propanoate 10a 
  According to the general procedure, employing 6a afforded compound 10a as a foam solid, 93% 
yield, [α]20D = -7.56 (c 1.73, MeOH); 1H NMR (500 MHz, MeOD) δ 8.30 (s, 1H, purin-H), 8.26 (s, 
1H, purin-H), 7.36-7.33 (m, 1H, Ar-H), 7.22 (d, J = 7.5 Hz, 1H, Ar-H), 7.15 (d, J = 9.8 Hz, 1H, 
Ar-H), 7.00-6.98 (m, 1H, Ar-H), 6.01 (d, J = 3.8 Hz, 1H, tetrahydrofuran-H), 4.85-4.83 (m, 2H, 
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benzyl-CH2), 4.35 (dd, J = 4.2, 4.7 Hz, 1 H, tetrahydrofuran-H), 4.13-4.10 (m, 1H, 
tetrahydrofuran-H), 3.63 (s, 3H, CH3O), 3.02-2.92 (m, 2H, isopropyl-CH and CH2-1H), 2.84-2.75 
(m, 3H, CH2 and CH2-1H), 2.48 (t, J = 7.0 Hz, 2H, CH2), 1.06 (d, J = 6.0 Hz, 3H, isopropyl-CH3), 
1.01 (d, J = 6.0 Hz, 3H, isopropyl-CH3); 13C NMR (500 MHz, MeOD) δ 173.5 (ester-C), 162.5 (d, 
J = 245.4 Hz, Ar-C), 154.6 (purin-C), 152.5 (purin-C), 142.0 (purin-C), 139.9 (purin-C), 129.9 
(Ar-C), 129.8 (Ar-C), 122.7 (d, J = 3 Hz, Ar-C), 119.6 (purin-C), 113.7 (d, J = 21.6 Hz, Ar-C), 
113.3 (d, J = 21.6 Hz, Ar-C), 88.9 (tetrahydrofuran-C), 83.8 (tetrahydrofuran-C), 73.1 
(tetrahydrofuran-C), 71.7 (tetrahydrofuran-C), 51.9 (MeO-C), 51.1 (CH2-C), 50.6 (CH2-C), 49.1 
(isopropyl-CH-C), 33.4 (isopropyl-CH3-C), 17.6 (isopropyl-CH3-C), 16.3; LRMS (ESI): m/z = 
525 [M + Na]+ ; HRMS-ESI (m/z): Calcd. For C24H32N6O5F (M+H)+: 503.2413; Found: 
503.2429.  
    
4.2.14.4. methyl 
3-((((2R,3S,4R,5R)-5-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-
2-yl)methyl)(isopropyl)amino)propanoate 10b 
   According to the general procedure, employing 6b afforded compound 10b as a foam solid, 
85% yield, [α]20D = -2.65 (c 0.57, MeOH); 1H NMR (500 MHz, MeOD) δ 8.30 (s, 2H, purin-C), 
7.42 (s, 1H, Ar-H), 7.33-7.26 (m, 3H, Ar-H), 6.01 (d, J = 3.8 Hz, 1H, tetrahydrofuran-H), 
4.85-4.83 (m, 2H, benzyl-CH2), 4.35 (dd, J = 4.2, 4.7 Hz, 1 H, tetrahydrofuran-H), 4.13-4.10 (m, 
1H, tetrahydrofuran-H), 3.63 (s, 3H, CH3O), 3.02-2.94 (m, 2H, ispropyl-CH and CH2-1H), 
2.85-2.82 (m, 3H, CH2 and CH2-1H), 2.50-2.47 (t, J = 7.0 Hz, 2H, CH2), 1.06 (d, J = 6.6 Hz, 3H, 
isopropyl-CH3), 1.01 (d, J = 6.6 Hz, 3H, isopropyl-CH3); 13C NMR (500 MHz, MeOD) δ 173.5 
(ester-C), 154.6 (purin-C), 152.5 (purin-C), 141.5 (purin-C), 140.0 (purin-C), 133.9 (Ar-C), 129.6 
(Ar-C), 129.4 (Ar-C), 127.0 (Ar-C), 126.7 (Ar-C), 125.4 (Ar-C), 119.8 (purin-C), 88.9 
(tetrahydrofuran-C), 83.8 (tetrahydrofuran-C), 73.1 (tetrahydrofuran-C), 71.7 (tetrahydrofuran-C), 
51.9 (MeO-C), 51.2 (CH2-C), 50.6 (CH2-C), 46.1 (isopropyl-CH-C), 33.3 (CH2-C), 17.5 
(isopropyl-CH3-C), 16.3 (isopropyl-CH3-C); LRMS (ESI): m/z = 519 [M + H]+. 
    
4.2.14.5. (2R,3R,4S,5R)-2-(6-((3-fluorobenzyl)amino)-9H-purin-9-yl)-5-(((3-hydroxypropyl) 
(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol 11a 
  According to the general procedure, employing 7a afforded compound 11a as a white solid, 88% 
yield, HPLC purity: 99.5%, method A; mp: 152-154 oC; [α]20D = 0.45 (c 0.67, MeOH); 1H NMR 
(500 MHz, MeOD) δ 8.30 (s, 2H, purin-H), 8.26 (s, 1H, purin-H), 7.36-7.33 (m, 1H, Ar-H), 7.22 
(d, J = 7.5 Hz, 1H, Ar-H), 7.15 (d, J = 9.8 Hz, 1H, Ar-H), 7.00-6.98 (m, 1H, Ar-H), 6.01 (d, J = 
3.8 Hz, 1H, tetrahydrofuran-H), 4.85-4.83 (m, 2H, benzyl-CH2), 4.35 (dd, J = 4.2, 4.7 Hz, 1 H, 
tetrahydrofuran-H), 4.19-4.18 (m, 1H, tetrahydrofuran-H), 3.65 (t, J = 5.5 Hz, 2H, CH2), 
3.17-3.13 (m, 1H, isopropyl-CH), 2.99-2.96 (m, 1H, CH2-1H), 2.89-2.85 (m, 1H, CH2-1H), 2.73 
(brs, 2H, CH2) 1.72 (t, J = 6.8 Hz, 2H, CH2), 1.10 (d, J = 6.5 Hz, 3H, isopropyl-CH3), 1.04 (d, J = 
6.5 Hz, 3H, isopropyl-CH3); 13C NMR (500 MHz, MeOD) δ 162.5 (d, J = 245 Hz, Ar-C), 154.6 
(purin-C), 152.5 (purin-C), 142.0 (purin-C), 139.9 (purin-C), 129.8 (Ar-C), 129.7 (Ar-C), 122.7 
(Ar-C), 119.7 (purin-C), 113.6 (d, J = 21.6 Hz, Ar-C), 113.5 (d, J = 21.6 Hz, Ar-C), 89.1 
(tetrahydrofuran-C), 83.0 (tetrahydrofuran-C), 73.2 (tetrahydrofuran-C), 72.1 (tetrahydrofuran-C), 
60.8 (CH2-C), 52.2(CH2-C), 50.9 (CH2-C), 48.9 (isopropyl-CH-C), 29.5 (CH2-C), 16.8 
(isopropyl-CH3-C), 16.1 (isopropyl-CH3-C); LRMS (ESI): m/z = 497 [M + Na]+; HRMS-ESI 
(m/z): Calcd. For C23H32N6O4F (M+H)+: 475.2464; Found: 475.2458. 
    
4.2.14.6. (2R,3R,4S,5R)-2-(6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-5-(((3-hydroxypropyl) 
(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol 11b 
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   According to the general procedure, employing 7b afforded compound 11b as a white solid, 
89% yield, HPLC purity: 92.7%, method A; mp: 144-147oC; [α]20D =-0.43 (c 0.70, MeOH); 1H 
NMR (500 MHz, MeOD) δ 8.30 (s, 1H, purin-H), 8.26 (s, 1H, purin-H), 7.42 (s, 1H, Ar-H), 
7.33-7.26 (m, 3H, Ar-H), 6.01 (d, J = 3.8 Hz, 1H, tetrahydrofuran-H), 4.85-4.83 (m, 2H, 
benzyl-CH2), 4.76 (brs, 1H, tetrahydrofuran-H), 4.30-4.28 (m, 1 H, tetrahydrofuran-H), 4.18-4.16 
(m, 1H, tetrahydrofuran-H), 3.62 (t, J = 6.8 Hz, 2H, CH2), 3.15-3.08 (m, 1H, isopropyl-CH), 
2.94-2.92 (m, 1H, CH2-1H), 2.82-2.81 (m, 1H, CH2-1H), 2.68 (brs, 2H, CH2), 1.69 (t, J = 6.9 Hz, 
2H, CH2), 1.06 (d, J = 6.5 Hz, 3H, isopropyl-CH3), 1.00 (d, J = 6.5 Hz, 3H, isopropyl-CH3); 13C 
NMR (500 MHz, MeOD) δ 154.6 (purin-C), 152.5 (purin-C), 141.5 (purin-C), 139.9 (purin-C), 
133.9 (Ar-C), 129.6 (Ar-C), 129.4 (Ar-C), 127.0 (Ar-C), 126.8 (Ar-C), 125.4 (Ar-C), 119.7 
(purin-C), 89.1 (tetrahydrofuran-C), 83.2 (tetrahydrofuran-C), 73.2 (tetrahydrofuran-C), 72.1 
(tetrahydrofuran-C), 60.9 (CH2-C), 52.1 (CH2-C), 50.7 (CH2-C), 48.2 (isopropyl-CH-C), 29.7 
(CH2-C), 16.9 (isopropyl-CH3-C), 16.1 (isopropyl-CH3-C); LRMS (ESI): m/z = 513 [M + Na]+; 
HRMS-ESI (m/z): Calcd. For C23H32N6O4Cl (M+H)+: 491.2168; Found: 491.2170. 
     
4.2.14.7. 
(2R,3S,4R,5R)-2-(((3-aminopropyl)(isopropyl)amino)methyl)-5-(6-((3-fluorobenzyl)amino)-9H-
purin-9-yl)tetrahydrofuran-3,4-diol 12a 
   According to the general procedure, employing 8a afforded compound 12a as an oil, 79% 
yield, [α]20D = 10.53 (c 1.02, MeOH); 1H NMR (500 MHz, MeOD) δ 8.30 (s, 1H, purin-H), 8.26 
(s, 1H, purin-H), 7.36-7.33 (m, 1H, Ar-H), 7.22 (d, J = 7.5 Hz, 1H, Ar-H), 7.15 (d, J = 9.8 Hz, 1H, 
Ar-H), 7.00-6.98 (m, 1H, Ar-H), 6.01 (d, J = 3.8 Hz, 1H, tetrahydrofuran-H), 4.82 (brs, 2H, 
benzyl-CH2), 4.81-4.79 (m, 1H, tetrahydrofuran-H), 4.40-4.38 (m, 1H, tetrahydrofuran-H), 
4.32-4.30 (m, 1H, tetrahydrofuran-), 3.12-2.98 (m, 7H, 3 × CH2 and isopropyl-CH), 1.92-1.90 
(brs, 2H, CH2), 1.19 (d, J = 5.3 Hz, 3H, isopropyl-CH3), 1.13 (d, J = 5.3 Hz, 3H, isopropyl-CH3); 
13C NMR (500 MHz, MeOD) δ 162.5 (d, J = 245.1 Hz, Ar-C), 154.7 (purin-C), 152.6 (purin-C), 
142.0 (purin-C), 139.8 (purin-C), 129.8 (d, J = 7.9 Hz, Ar-C), 129.4 (Ar-C), 122.8 (d, J = 3.2 Hz, 
Ar-C), 119.8 (purin-C), 113.6 (d, J = 21.8 Hz, Ar-C), 113.3 (d, J = 21.6 Hz, Ar-C), 89.5 
(tetrahydrofuran-C), 81.4 (tetrahydrofuran-C), 73.1 (tetrahydrofuran-C), 72.1 (tetrahydrofuran-C), 
52.1 (CH2-C), 48.8 (isopropyl-CH-C), 29.4 (CH2-C), 23.3 (CH2-C), 16.3 (isopropyl-CH3-C), 15.4 
(isopropyl-CH3-C); LRMS (ESI): m/z = 496 [M + Na]+ ; HRMS-ESI (m/z): Calcd. For 
C23H33N7O3F (M+H)+: 474.2623; Found: 474.2625. 
     
4.2.14.8. 
(2R,3S,4R,5R)-2-(((3-aminopropyl)(isopropyl)amino)methyl)-5-(6-((3-chlorobenzyl)amino)-9H-
purin-9-yl)tetrahydrofuran-3,4-diol 12b 
According to the general procedure, employing 8b afforded compound 12b as an oil, 85% yield, 
[α]20D = 8.74 (c 1.09, MeOH); 1H NMR (500 MHz, MeOD) δ 8.32 (s, 1H, purin-H), 8.27 (s, 1H, 
purin-H), 7.42 (s, 1H, Ar-H), 7.34-7.27 (m, 3H, Ar-H), 6.04 (d, J = 4.1 Hz, 1H, 
tetrahydrofuran-H), 4.85 (brs, 2H, benzyl-CH2), 4.81-4.80 (m, 1H, tetrahydrofuran-H), 4.34 (t, J = 
5.3 Hz, 1H, tetrahydrofuran-H), 4.25-4.20 (m, 1H, tetrahydrofuran-H), 3.20-3.15 (m, 1H, 
isopropyl-CH), 3.07 (t, J = 6.0 Hz, 2H, CH2), 2.95-2.78 (m, 4H, 2 × CH2), 1.81-1.78 (m, 2H, 
CH2), 1.10 (d, J = 6.0 Hz, 3H, isopropyl-CH3), 1.04 (d, J = 6.0 Hz, 3H, isopropyl-CH3); 13C NMR 
(500 MHz, MeOD) δ 154.6 (purin-C), 152.5 (purin-C), 141.5 (purin-C), 139.9 (purin-C), 133.9 
(Ar-C), 129.6 (Ar-C), 129.4 (Ar-C), 127.0 (Ar-C), 126.8 (Ar-C), 125.4 (Ar-C), 119.7 (purin-C), 
89.1 (tetrahydrofuran-C), 82.3 (tetrahydrofuran-C), 73.2 (tetrahydrofuran-C), 72.1 
(tetrahydrofuran-C), 52.0 (CH2-C), 49.1 (isopropyl-CH-C), 39.6 (CH2-C), 29.4 (CH2-C), 23.5 
(CH2-C), 16.6 (isopropyl-CH3-C), 15.4 (isopropyl-CH3-C); LRMS (ESI): m/z = 512 [M + Na]+; 
HRMS-ESI (m/z): Calcd. For C23H33N7O3Cl (M+H)+: 490.2328; Found: 490.2327. 
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4.3. HPLC purity determination  
   All samples were performed on an Agilent 1260 HPLC-UV system, using Method A, B, or C 
as follows. Solvent A = Acetonitrile; solvent B = Tetramethylammonium hydroxide solution, 
solvent C = Methonal; column (Waters Xterra RP18, 4.6 mm × 250 mm, 5 µm), 40 oC; UV at 254 
nm. 
   Preparation of solvent B：To a stirred solution tetramethylammonium hydroxide (4.53 g) in 
H2O (1000 mL) was added triethylamine (0.1 mL), and then adjusted to pH 9.0 by phosphoric 
acid.  
 
   Method A: Solvent A : Solvent B = 50 : 50, flow: 0.7 mL/min, 16 min; 
   Method B: Solvent A : Solvent B = 50 : 50, flow: 1.5 mL/min, 16 min; 
   Method C: Solvent C : Solvent B = 60 : 40, flow:1.2 mL/min, 20 min.  
 
4.4. Anti-ZIKV Assay 
   The reference drug Sinefungin and EPZ004777 were purchased from STEMCELL 
Technologies. The ZIKV was obtained from the Institute of Microbiology, Chinese Academy of 
Sciences, Beijing, China. 
   BHK cells were seeded into 96-well plate using DMEM supplemented with 10% FBS and 
penicillin and streptomycin (100 units/ml and 100 µg/ml, respectively) at a density of 5,000 cells 
per well. After 24 h incubation at 37  with 5% CO℃ 2 , original medium was changed into 
maintenance medium (DMEM supplemented with 2% FBS and P/S) in a volume of 100 µL. Zika 
virus stocks propagated in Vero cells were diluted to 100TCID50 and added 50 µL to each virus 
control and administered well. The compounds that diluted from 50 µM by 3-fold dilution in 
maintenance medium were added to administered wells. The wells were supplemented with 
maintenance medium to 200 µL. The plates were incubated for 8 days until the CPE reached 
100%. The cell viability was measured by Cell Titer-Glo® luminescent cell viability kit 
according to the manufacturer’s instructions. The IC50 values were calculated by Origin 8.0. 
4.5. Cytotoxicity determination 
   Various concentrations of compounds from 200 µM to 0.09 µM by 3-fold dilution were 
diluted in maintenance medium. BHK cells were seeded in 96-well plate at a density of 5,000 
cells per well and allowed to recover for 24 h. Culture medium was replaced by maintenance 
medium containing the compound to be examined or drug-free. After 8 days’ exposure, cell 
viability was also determined with Cell Titer-Glo reagent. The CC50 values were calculated by 
Origin 8.0. 
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ABBREVIATIONS 
ZIKV, Zika virus; YFV, yellow fever virus; DENV, dengue virus; WNV, west nile virus; 
WHO, world health organization; SIN, Sinefungin; SAM, S-Adenosyl methionine; Mtases, 
Methyltransferases; SAH, S-adenosyl-l-homocysteine; NITD, Novartis Institute for Tropical 
Disease. 
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Highlights: 
1. SIN (IC50 > 50 µm) proved to be inactive against ZIKV. 
2. 1ad-af, 1ba-bb, and 1bf-bh displays potent anti-ZIKV activity (IC50=4.56-20.16µM). 
3. 9a exhibits good activity (IC50=29.98µM) and acceptable cytotoxicity (CC50>200 µM).   
